Full Text View
Tabular View
No Study Results Posted
Related Studies
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
This study is ongoing, but not recruiting participants.
Study NCT01078961   Information provided by Dana-Farber Cancer Institute

First Received on March 1, 2010.   Last Updated on January 2, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
bortezomib
sorafenib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Massachusetts General Hospital
Dana-Farber Cancer Institute
Beth Isreal Deaconess Medical Center
Brigham and Women's Hospital
Bayer
Millennium Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services